LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

95.97 0.69

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

95.02

Максимум

97.78

Ключови измерители

By Trading Economics

Приходи

2.9M

-47M

Продажби

16M

49M

Марж на печалбата

-96.144

Служители

283

EBITDA

6.9M

-40M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+17.34% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

672M

6.6B

Предишно отваряне

95.28

Предишно затваряне

95.97

Настроения в новините

By Acuity

20%

80%

43 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.09.2025 г., 17:03 ч. UTC

Значими двигатели на пазара

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16.09.2025 г., 16:49 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

GD Culture Shares Drop After Deal for Pallas Capital

16.09.2025 г., 16:11 ч. UTC

Значими двигатели на пазара

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16.09.2025 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Decline as Yen Strengthens -- Market Talk

16.09.2025 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16.09.2025 г., 23:20 ч. UTC

Пазарно говорене

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16.09.2025 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16.09.2025 г., 20:51 ч. UTC

Пазарно говорене

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

16.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

16.09.2025 г., 20:25 ч. UTC

Печалби

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16.09.2025 г., 20:24 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16.09.2025 г., 19:19 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16.09.2025 г., 18:52 ч. UTC

Пазарно говорене

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16.09.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.09.2025 г., 18:44 ч. UTC

Пазарно говорене

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16.09.2025 г., 18:40 ч. UTC

Придобивния, сливания и поглъщания

Details Emerge on U.S.-China TikTok Deal -- WSJ

16.09.2025 г., 18:38 ч. UTC

Пазарно говорене

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16.09.2025 г., 18:19 ч. UTC

Пазарно говорене

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16.09.2025 г., 18:01 ч. UTC

Пазарно говорене

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16.09.2025 г., 17:34 ч. UTC

Пазарно говорене

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16.09.2025 г., 16:53 ч. UTC

Печалби

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16.09.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

16.09.2025 г., 16:15 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Commodities Roundup: Market Talk

16.09.2025 г., 16:09 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Energy Roundup: Market Talk

16.09.2025 г., 16:09 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16.09.2025 г., 15:35 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.09.2025 г., 15:35 ч. UTC

Пазарно говорене

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16.09.2025 г., 15:22 ч. UTC

Пазарно говорене

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16.09.2025 г., 15:21 ч. UTC

Пазарно говорене

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

17.34% нагоре

12-месечна прогноза

Среден 112.08 USD  17.34%

Висок 135 USD

Нисък 95 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

13

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

43 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat